INBX NASDAQ
Inhibrx Biosciences Inc.
1W: +0.4%
1M: -6.0%
3M: +20.7%
YTD: +27.5%
1Y: +67.0%
$95.66
+7.05 (+7.96%)
Weekly Expected Move ±7.2%
$80
$87
$93
$100
$107
Credit Risk of going bust: lower than 68% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.08 (down 99.9%), Inhibrx Biosciences Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $1.30B.
Distance to default 7.31 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.9M (short-term plus half of long-term), stock volatility 76.3%; Altman Z'' -7.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.08 (down 99.9%), Inhibrx Biosciences Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $1.30B.
Distance to default 7.31 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.9M (short-term plus half of long-term), stock volatility 76.3%; Altman Z'' -7.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$6.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.4B
52W Range57.3-155.29
Volume373,943
Avg Volume292,160
Beta3.82
Dividend—
Analyst Ratings
Company Info
CEOMark Lappe
Employees110
SectorHealthcare
IndustryBiotechnology
IPO Date2024-05-29
Websiteinhibrx.com
11025 North Torrey Pines Road
La Jolla, CA 92037
US
La Jolla, CA 92037
US
858-795-4220
About Inhibrx Biosciences Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Latest News
Avoiding Lag: Real-Time Signals in (INBX) Movement - Stock Traders Daily
Inhibrx Biosciences, Inc. (INBX) stock price, news, quote and history - Yahoo Finance UK
Inhibrx Stock Price Forecast. Should You Buy INBX? - StockInvest.us
Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price
Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price - Yahoo Finance
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lappe Mark | P-Purchase | 2,470 | $84.07 | 2026-10-14 |
| Lappe Mark | P-Purchase | 2,470 | $85.00 | 2026-10-14 |
| Lappe Mark | P-Purchase | 100 | $85.76 | 2026-10-14 |
| Lappe Mark | P-Purchase | 2,449 | $84.07 | 2026-10-14 |
| Lappe Mark | P-Purchase | 2,451 | $85.00 | 2026-10-14 |